...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Trodelvy - development history and valuations along the way

In 2019, before Trodelvy received FDA approvals, Immunomedics was able to license Trodelvy to Everest Medicines for $65M upfront and $710M in potential milestone payments.  This should be a useful comparison when valuing ZEN-3694.  If ZEN-3694 was licensed in similiar Asian markets for Prostate Cancer, I would expect 5X (?) what Immunomedics got for Trodelvy due to the 10X market size.

2013 - Immunomedics announces they have received fast track designation from FDA for Sacituzumab govitecan (later to be named Trodelvy) for non-small cell lung cancer, small cell lung cancer and metastatic TNBC.

2016 -  Immunomedics announced that Trodelvy had received an FDA breakthrough therapy designation for treatment of people with TNBC.

2019 - Immunomedics licenses Trodelvy’s Asian rights to Everest Medicines.  (Asian rights includes China, South Korea, Singapore, Indonesia, Philipines, Vietnam, Thailand, Malayasia and Mongolia.)  $65 M upfront payment with up to $710 M in potential milestone payments.

2020 - (April) FDA granted accelerated approval for treatment of TNBC.

2020 – (October) Gilead acquires Immunomedics for $21 Billion.

2021 – (April) FDA grants regular approval for treatment of TNBC.

2021 – (April) FDA grants accelerated approval for treatment of Urothelial cancer aka Urinary tract/Bladder cancer.

2022 – (June) Final data from Phase 3 ASCENT trial published.  Halted early after obtaining positive efficacy data.

2022 – (August) Gilead acquires remaining world wide rights of Trodelvy for $445 M from Everest Medicines.  $280M upfront and $175M in milestone payments.

2023 (Feb) FDA grants approval for treatment of HR+/HER2- breast cancer.

Share
New Message
Please login to post a reply